HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, Nov. 25, 2020 (HealthDay News) -- Apolipoprotein E4 (ApoE4) genotype, anxiety, and lower hippocampal (HV) and entorhinal cortex volumes (ERV) are associated with an elevated progression rate from mild cognitive impairment (MCI) to Alzheimer disease (AD), according to a study scheduled for presentation at the annual meeting of the Radiological Society of North America, held virtually from Nov. 29 to Dec. 5.
Jenny L. Uber, from the Medical University of South Carolina in Charleston, and colleagues examined the effect of anxiety and depression on progression of MCI to AD in a population of 339 patients (mean age, 72 years) with a baseline diagnosis of MCI. Of these patients, 72 and 267 progressed to AD and remained stable, respectively.
The researchers found that among MCI patients with and without progression to AD, there was no difference in age, gender, or years of education. Significantly lower normalized HV and ERV, greater frequency of the ApoE4 allele, and greater maximum levels of anxiety and depression were seen for patients who progressed to AD. An increased rate of progression from MCI to AD was seen in association with the presence of ApoE4, a higher level of anxiety, and lower HV and ERV.
"We need to better understand the association between anxiety disorders and cognitive decline," a coauthor said in a statement. "If we were able in the future to find that anxiety is actually causing progression, then we should more aggressively screen for anxiety disorders in the elderly."
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 25, 2022